Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1698877 | 0.82 | IRAK4 (0.50) | IRAK4CHRM3CHRNB2CHRNA4CHRM2 | |
| Hydrochloric Acid SCHEMBL7518074 | 0.78 | CHRNB2 (0.59) | CHRM3CHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL31471103 | 0.77 | BRD4 (0.60) | BRD4 | |
| Hydrochloric Acid SCHEMBL1241547 | 0.76 | BRD4 (0.43) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL7158103 | 0.75 | TSHR (0.50) | CHRM3CHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL12327315 | 0.75 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7267932 | 0.73 | BRD4 (0.56) | BRD4 | |
| SCHEMBL1240609 | 0.73 | ALOX5AP (0.47) | CHRM2MAPT | |
| SCHEMBL27492257 | 0.73 | BRD4 (0.58) | BRD4MAPT | |
| SCHEMBL16661155 | 0.73 | DGAT1 (0.46) | IRAK4SLC6A2SLC6A4SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | BRD4 2273/4885IRAK4 4849/4885CHRM3 2122/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | BRD4 2273/4885IRAK4 4849/4885CHRM3 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.